Abivax SA (ABVX) Stock: Buy, Sell, or Hold?
ABVX - Abivax SA American Depositary Shares
$113.58
-5.06 (-4.27%)
▼
5d:
-1.05%
30d:
-6.48%
90d:
+17.64%
HOLD
MODERATE Confidence
Analysis Updated: Sep 14, 2026 12:00 AM ET
Earnings: Sep 21, 2026
5d
Get Alerted When ABVX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ABVX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ABVX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ABVX is currently trading at $113.58, which is considered fair relative to its 30-day fair value range of $114.11 to $124.88.
Technical Outlook: Technically, ABVX is in a strong uptrend. The price is currently testing key support at $110.22. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.3% recently.
Market Sentiment: The stock scores a mixed 48/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $165.00 (+45.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ABVX is in a strong uptrend. The price is currently testing key support at $110.22. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.3% recently.
Market Sentiment: The stock scores a mixed 48/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $165.00 (+45.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$114.11 -
$124.88
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (48/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.3%)
- BULLISH: Trading 45.3% below Wall St target ($165.00)
- NEUTRAL: Bottoming setup forming (48/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$114.11 -
$124.88
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$110.22
Resistance Level
$120.63
Current Trend
Strong Uptrend
Technical data as of
Sep 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-33.98
Wall Street Target
$165.00
(+45.3%)
Revenue Growth (YoY)
35.2%
Share & Embed Analysis
Last updated: September 15, 2026 7:05 AM ET
Data refreshes hourly during market hours. Next update: 8:05 AM
Data refreshes hourly during market hours. Next update: 8:05 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABVX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 34 SELL |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 35 SELL |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$48 | 44 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 43 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$137 | 55 HOLD |
